**SECURITIES AND EXCHANGE COMMISSION****Washington, D.C. 20549**

----

**FORM 10-Q/AAMENDMENT NO. 1**

| ý |   | **QUARTERLY REPORT PURSUANT TO  SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
|--------|--------|---------------------------------------------------------------------------------------------------|
|   |   | **For  the Quarter Ended September 30, 2002**                                                |

**Commission File Number 0-21481**

 

**TRANSKARYOTIC THERAPIES, INC.**(Exactname of registrant as specified in its charter) 

| **Delaware**  (State or other jurisdiction of incorporation or organization)           |   | **04-3027191**  (I.R.S. Employer Identification No.) |
|----------------------------------------------------------------------------------------|--------|------------------------------------------------------|
|                                                                                   |   |                                                 |
| **700  Main Street Cambridge, Massachusetts**(Address of  principal executive offices) |   | **02139**  (Zip Code)                                |
|                                                                                   |   |                                                 |
| Registrant’s telephone  number, including area code: **(617) 349-0200**           |

----

        Indicateby check mark whether the registrant (1) has filed all reports required tobe filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that theregistrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.                                                                                                 Yes ý    No o

        AtOctober 31, 2002, there were 34,842,922 shares of Common Stock, $.01 parvalue, outstanding.

 

 

 

----

 

**Explanatory Note**

        We are filing thisamendment no. 1 to our Quarterly Report on Form 10-Q for the periodended September 30, 2002 on this Form 10-Q/A solely to refileExhibit 10.32.

 

----

**SIGNATURES**

        Pursuantto the requirements of the Securities Exchange Act of 1934, the Registrant hasduly caused this report to be signed on its behalf by the undersigned thereuntoduly authorized. 
|                      | TRANSKARYOTIC THERAPIES,  INC. |
|---------------------------|--------------------------------|
|                      |                           |   |
|  Date: April 3, 2003 | By:                            | /s/ Daniel E.  Geffken |
|                      |                           | Daniel E. Geffken |
|                      |                           | *Senior Vice President, Finance and* |
|                      |                           | *Chief Financial Officer (Principal* |
|                      |                           | *Financial and Accounting Officer)* |

 

 

----

 

**CERTIFICATIONS**

        I,Michael J. Astrue, certify that:

        (1)I have reviewed this quarterly report on Form 10-Q/A of TranskaryoticTherapies, Inc.; and

        (2)Based on my knowledge, this quarterly report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this quarterlyreport. 
|  Dated: April 3, 2003 |                            |
|----------------------------|---------------------------------|
|                       | /s/ Michael J. Astrue           |
|                       | Michael J. Astrue               |
|                       | *President and Chief Executive* |
|                       | *Officer*                       |

 

----

        I,Daniel E. Geffken, certify that:

        (1)I have reviewed this quarterly report on Form 10-Q/A of TranskaryoticTherapies, Inc.; and

        (2)Based on my knowledge, this quarterly report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this quarterlyreport. 
|  Dated: April 3, 2003 |                                 |
|----------------------------|--------------------------------------|
|                       | /s/ Daniel E. Geffken                |
|                       | Daniel E. Geffken                    |
|                       | *Senior Vice President, Finance and* |
|                       | *Chief Financial Officer*            |

 

 

----

**EXHIBIT INDEX**
| 10.32# |   | Commercial Supply and  Process Validation Agreement, entered into as of December 6, 1999, by and  between TKT and Chesapeake Biological Laboratories, Inc. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

#

Confidential treatmentrequested as to certain portions pursuant to Rule 24-b-2 promulgated underthe Exchange Act of 1934, as amended.

 

 

----